“The current BN162 (Comirnaty) vaccine can induce antibody formation against the alpha and beta variants under laboratory conditions. No data is available on later variants. There has been no variant adaptation of the vaccine since the start of the vaccination campaign, and no adaptation is planned for the boosters. There is no general recommendation for a booster, and the benefits of vaccination must always be weighed up on an individual basis,”

BioNTech

BioNTech Quote on COVID-19 Vaccine Safety and Efficacy – Honesty and Risks Explained

0 Comments/in BioNTech

“We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine and/or variant-specific formulations to obtain permanent regulatory approval in the United States, the United Kingdom, the European Union, or other countries where it has been authorized for emergency use or granted conditional marketing approval. Significant adverse events may occur during our clinical trials or even after receiving regulatory approval, which could delay or terminate clinical trials, delay or prevent regulatory approval or market acceptance of any of our product candidates.”

BioNTech

Archive for category: BioNTech